Piperazine Citrate Tablets BP 500 mg

Summary of Product characteristics

                                Revised: 11
th
December 2008
AN: 02300/2007
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT.
Piperazine Citrate Tablets BP 500mg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION.
Each tablet contains:
ACTIVE SUBSTANCE: MG
Piperazine Citrate………………………….. 500.0
For a full list of excipients, see section 6.1
3. PHARMACEUTICAL FORM.
Tablet
White Circular, biconvex, tablets. Scored on one side.
4. CLINICAL PARTICULARS.
4.1 TARGET SPECIES;
Dogs and cats
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES;
For the treatment of Roundworms (Ascarids) and Hookworms in both dogs
and cats.
4.3 CONTRA INDICATION;
Do not give more than 6 tablets in any one dose. If no vomiting occurs
the remaining
dose may be given after 3 hours.
Do not repeat the treatment if vomiting occurs shortly after dosing.
Do not administer to puppies or kittens weighing less than 1.25Kg.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES;
None
4.5 SPECIAL PRECAUTIONS FOR USE.
I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Consult a veterinary surgeon before dosing animals with a history of
epilepsy or
severe renal dysfunction.
Do not use if your pet is sick or recovering from an illness.
Animals weighing less than 1.25Kg should be treated with a suitable
product
authorised for this purpose.
Revised: 11
th
December 2008
AN: 02300/2007
II) SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
MEDICINAL
PRODUCT TO ANIMALS
Wash hands immediately after handling the tablets.
Accidental eye contact – rinse thoroughly with clean running water.
If irritation
persists seek medical advice.
Accidental ingestion by humans – drink plenty of water and seek
medical advice.
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS);
None reported
4.7 USE DURING PREGNANCY, LACTATION OR LAY;
Not applicable.
4.8 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION;
INTERACTION WITH MEDICINAL PRODUCTS – None known.
OTHER - None known.
4.9 AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE;
The tablets are bes
                                
                                Read the complete document